Literature DB >> 19915602

Clinical trial design in neonatal pharmacology: effect of center differences, with lessons from the Pediatric Oncology Cooperative Research experience.

C Moran1, P B Smith, M Cohen-Wolkowiez, D K Benjamin.   

Abstract

Survival for premature neonates has improved dramatically over the past 20 years; however, there has been minimal improvement in prematurity-associated morbidities. Morbidity rates and assessment of outcomes vary across neonatology intensive care units (NICUs). Here, we address the reasons underlying these differences, note the impact that this center variation has on trial design and interpretation, and highlight the success of the efforts in pediatric oncology to develop standards of care through the conduct of multicenter clinical trials.

Entities:  

Mesh:

Year:  2009        PMID: 19915602      PMCID: PMC2782890          DOI: 10.1038/clpt.2009.175

Source DB:  PubMed          Journal:  Clin Pharmacol Ther        ISSN: 0009-9236            Impact factor:   6.875


  5 in total

1.  Fluconazole prophylaxis against fungal colonization and infection in preterm infants.

Authors:  D Kaufman; R Boyle; K C Hazen; J T Patrie; M Robinson; L G Donowitz
Journal:  N Engl J Med       Date:  2001-12-06       Impact factor: 91.245

2.  The association of third-generation cephalosporin use and invasive candidiasis in extremely low birth-weight infants.

Authors:  C Michael Cotten; Scott McDonald; Barbara Stoll; Ronald N Goldberg; Kenneth Poole; Daniel K Benjamin
Journal:  Pediatrics       Date:  2006-08       Impact factor: 7.124

3.  Very low birth weight outcomes of the National Institute of Child health and human development neonatal research network, January 1995 through December 1996. NICHD Neonatal Research Network.

Authors:  J A Lemons; C R Bauer; W Oh; S B Korones; L A Papile; B J Stoll; J Verter; M Temprosa; L L Wright; R A Ehrenkranz; A A Fanaroff; A Stark; W Carlo; J E Tyson; E F Donovan; S Shankaran; D K Stevenson
Journal:  Pediatrics       Date:  2001-01       Impact factor: 7.124

4.  Trends in neonatal morbidity and mortality for very low birthweight infants.

Authors:  Avroy A Fanaroff; Barbara J Stoll; Linda L Wright; Waldemar A Carlo; Richard A Ehrenkranz; Ann R Stark; Charles R Bauer; Edward F Donovan; Sheldon B Korones; Abbot R Laptook; James A Lemons; William Oh; Lu-Ann Papile; Seetha Shankaran; David K Stevenson; Jon E Tyson; W Kenneth Poole
Journal:  Am J Obstet Gynecol       Date:  2007-02       Impact factor: 8.661

Review 5.  Progress in childhood cancer: 50 years of research collaboration, a report from the Children's Oncology Group.

Authors:  Maura O'Leary; Mark Krailo; James R Anderson; Gregory H Reaman
Journal:  Semin Oncol       Date:  2008-10       Impact factor: 4.929

  5 in total
  4 in total

1.  Pediatric rheumatic disease: Standards of care for JIA--the basic foundation for quality.

Authors:  Christy Sandborg
Journal:  Nat Rev Rheumatol       Date:  2010-07       Impact factor: 20.543

2.  Neonatal pharmacology: rational therapeutics for the most vulnerable.

Authors:  L James; S Ito
Journal:  Clin Pharmacol Ther       Date:  2009-12       Impact factor: 6.875

3.  Study factors associated with the incompletion of clinical trials that include pediatric patients: a retrospective analysis of the European Clinical Trials Database and a lesson from the European region.

Authors:  Nanae Tanemura; Tsuyoshi Sasaki; Junko Sato; Hisashi Urushihara
Journal:  Trials       Date:  2021-03-12       Impact factor: 2.279

4.  A Delphi process to optimize quality and performance of drug evaluation in neonates.

Authors:  Frederic Legrand; Rym Boulkedid; Valery Elie; Stephanie Leroux; Elizabeth Valls; Adolfo Valls-i-Soler; Johannes N Van den Anker; Evelyne Jacqz-Aigrain
Journal:  PLoS One       Date:  2014-09-11       Impact factor: 3.240

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.